Olaparib for high-risk, early-stage breast cancer approved in Europe 04 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that the precision medicine olaparib has been approved in Europe for people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide